COVID-19 patients have significantly low counts of a cell type that plays a crucial role in immune response, with lower numbers of these cells indicating more severe disease, according to a study whose findings may lead to the development of new therapeutics against the disease.
The study, published in the journal Frontiers in Immunology, assessed COVID-19 patients in China, and found that an adverse immune response triggered in the body may affect disease severity by lowering the counts of T cells, which are a type white blood cells that play important roles in the immune system.
According to the scientists, including those from the Army Medical University in China, COVID-19 patients had a high concentration of cytokines, a protein that normally helps fight off infection.
They said an increased concentration of these molecules can trigger an excessive inflammatory response known as a cytokine storm, which causes the proteins to attack healthy cells.
Coronavirus, the study said, does not attack T cells directly, but rather triggers the cytokine release, which then drives the depletion and exhaustion of T cells.
The findings, according to the researchers, offer clues on how to target treatment for COVID-19.
"We should pay more attention to T cell counts and their function, rather than respiratory function of patients," said study co-author Yongwen Chen of Third Military Medical University in China, adding that "more urgent, early intervention may be required in patients with low T lymphocyte counts."
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
